Rapport Therapeutics, Inc. (RAPP)

NASDAQ: RAPP · Real-Time Price · USD

46.98

+1.49 (3.28%)

At close: Aug 10, 2026, 4:00 PM EDT

47.30

+0.32 (0.68%)

After-hours: Aug 10, 2026, 4:18 PM EDT

Rapport Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-137.16	-111.48	-78.31	-34.79
Depreciation & Amortization	0.96	1.02	0.84	0.11
Stock-Based Compensation	24.59	18.86	10.24	3.53
Other Adjustments	1.58	0.64	4.82	1.32
Change in Receivables	-0.29	-	-	-
Changes in Accounts Payable	-0.38	2.22	-0.35	0.86
Changes in Accrued Expenses	16.47	6.17	0.37	5.38
Changes in Other Operating Activities	-2.45	-4.88	-2.44	-3.58
Operating Cash Flow	-96.68	-87.47	-64.83	-27.18
Operating Cash Flow Growth	-	-	-	-
Capital Expenditures	-0.47	-0.62	-2.41	-1.64
Purchases of Investments	-368.74	-354.78	-377.53	-77.22
Proceeds from Sale of Investments	201.45	167.93	209.8	-
Investing Cash Flow	-167.56	-187.47	-170.14	-78.86
Issuance of Common Stock	3.74	270.79	157.71	0.05
Repurchase of Common Stock	-0.01	-0	-	-0
Net Common Stock Issued (Repurchased)	3.74	270.79	157.71	0.05
Issuance of Preferred Stock	-	-	63.91	145.22
Net Preferred Stock Issued (Repurchased)	-	-	63.91	145.22
Other Financing Activities	-0.45	-	-	-0.13
Financing Cash Flow	272.79	270.79	221.63	145.14
Net Cash Flow	8.55	-4.16	-13.34	39.1
Free Cash Flow	-97.15	-88.09	-67.23	-28.82
Free Cash Flow Growth	-	-	-	-
FCF Margin	-485.75%	-	-	-
Free Cash Flow Per Share	-2.16	-2.26	-3.24	-19.14
Levered Free Cash Flow	-123.03	-107.58	-82.29	-33.66
Unlevered Free Cash Flow	-139.38	-121.2	-87.04	-35.06

SEC Filings: 10-K · 10-Q